Literature DB >> 27460425

Precision assessment of heterogeneity of lymphedema phenotype, genotypes and risk prediction.

Mei R Fu1, Yvette P Conley2, Deborah Axelrod3, Amber A Guth3, Gary Yu4, Jason Fletcher4, David Zagzag5.   

Abstract

Lymphedema following breast cancer surgery is considered to be mainly due to the mechanical injury from surgery. Recent research identified that inflammation-infection and obesity may be the important predictors for lymphedema. The purpose of this exploratory research was to prospectively examine phenotype of arm lymphedema defined by limb volume and lymphedema symptoms in relation to inflammatory genes in women treated for breast cancer. A prospective, descriptive and repeated-measure design using candidate gene association method was used to enroll 140 women at pre-surgery and followed at 4-8 weeks and 12 months post-surgery. Arm lymphedema was determined by a perometer measurement of ≥5% limb volume increase from baseline of pre-surgery. Lymphedema symptom phenotype was evaluated using a reliable and valid instrument. Saliva samples were collected for DNA extraction. Genes known for inflammation were evaluated, including lymphatic specific growth factors (VEGF-C & VEGF-D), cytokines (IL1-a, IL-4, IL6, IL8, IL10, & IL13), and tumor necrosis factor-a (TNF-a). No significant associations were found between arm lymphedema phenotype and any inflammatory genetic variations. IL1-a rs17561 was marginally associated with symptom count phenotype of ≥8 symptoms. IL-4 rs2070874 was significantly associated with phenotype of impaired limb mobility and fluid accumulation. Phenotype of fluid accumulation was significantly associated with IL6 rs1800795, IL4 rs2243250 and IL4 rs2070874. Phenotype of discomfort was significantly associated with VEGF-C rs3775203 and IL13 rs1800925. Precision assessment of heterogeneity of lymphedema phenotype and understanding the biological mechanism of each phenotype through the exploration of inherited genetic susceptibility is essential for finding a cure. Further exploration of investigative intervention in the context of genotype and gene expressions would advance our understanding of heterogeneity of lymphedema phenotype.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Genotype; Lymphedema; Phenotype; Risk; Symptoms

Mesh:

Substances:

Year:  2016        PMID: 27460425      PMCID: PMC5014618          DOI: 10.1016/j.breast.2016.06.023

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  37 in total

1.  Possible genetic predisposition to lymphedema after breast cancer.

Authors:  Beth Newman; Felicity Lose; Mary-Anne Kedda; Mathias Francois; Kaltin Ferguson; Monika Janda; Patsy Yates; Amanda B Spurdle; Sandra C Hayes
Journal:  Lymphat Res Biol       Date:  2012-03-09       Impact factor: 2.589

2.  A note on exact tests of Hardy-Weinberg equilibrium.

Authors:  Janis E Wigginton; David J Cutler; Goncalo R Abecasis
Journal:  Am J Hum Genet       Date:  2005-03-23       Impact factor: 11.025

3.  A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population.

Authors:  Jane M Armer; Bob R Stewart
Journal:  Lymphat Res Biol       Date:  2005       Impact factor: 2.589

4.  Tag SNP selection for candidate gene association studies using HapMap and gene resequencing data.

Authors:  Zongli Xu; Norman L Kaplan; Jack A Taylor
Journal:  Eur J Hum Genet       Date:  2007-06-13       Impact factor: 4.246

5.  Minimal limb volume change has a significant impact on breast cancer survivors.

Authors:  J N Cormier; Y Xing; I Zaniletti; R L Askew; B R Stewart; J M Armer
Journal:  Lymphology       Date:  2009-12       Impact factor: 1.286

6.  Rational inferences about departures from Hardy-Weinberg equilibrium.

Authors:  Jacqueline K Wittke-Thompson; Anna Pluzhnikov; Nancy J Cox
Journal:  Am J Hum Genet       Date:  2005-04-15       Impact factor: 11.025

7.  The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors.

Authors:  Mei R Fu; Constance M Chen; Judith Haber; Amber A Guth; Deborah Axelrod
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

8.  Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women.

Authors:  Susanne Henningsson; Anna Håkansson; Lars Westberg; Fariba Baghaei; Roland Rosmond; Göran Holm; Agneta Ekman; Hans Nissbrandt; Elias Eriksson
Journal:  Obesity (Silver Spring)       Date:  2006-11       Impact factor: 5.002

9.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

View more
  16 in total

1.  Primer in Genetics and Genomics, Article 5-Further Defining the Concepts of Genotype and Phenotype and Exploring Genotype-Phenotype Associations.

Authors:  Fay Wright; Kristen Fessele
Journal:  Biol Res Nurs       Date:  2017-10       Impact factor: 2.522

2.  Associating Symptom Phenotype and Genotype in Preeclampsia.

Authors:  Sandra A Founds; Eleni Tsigas; Dianxu Ren; M Michael Barmada
Journal:  Biol Res Nurs       Date:  2018-01-22       Impact factor: 2.522

3.  Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem.

Authors:  Olga V Saik; Vadim V Nimaev; Dilovarkhuja B Usmonov; Pavel S Demenkov; Timofey V Ivanisenko; Inna N Lavrik; Vladimir A Ivanisenko
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

Review 4.  Lymphedema following cancer therapy: overview and options.

Authors:  Michael Bernas; Saskia R J Thiadens; Betty Smoot; Jane M Armer; Paula Stewart; Jay Granzow
Journal:  Clin Exp Metastasis       Date:  2018-05-17       Impact factor: 5.150

5.  Real-time electronic patient evaluation of lymphedema symptoms, referral, and satisfaction: a cross-sectional study.

Authors:  Jennifer L Nahum; Mei R Fu; Joan Scagliola; Martha Rodorigo; Sandy Tobik; Amber Guth; Deborah Axelrod
Journal:  Mhealth       Date:  2021-04-20

Review 6.  Inflammatory Manifestations of Lymphedema.

Authors:  Catherine L Ly; Raghu P Kataru; Babak J Mehrara
Journal:  Int J Mol Sci       Date:  2017-01-17       Impact factor: 5.923

Review 7.  Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema.

Authors:  Marco Invernizzi; Gianluca Lopez; Anna Michelotti; Konstantinos Venetis; Elham Sajjadi; Leticia De Mattos-Arruda; Michele Ghidini; Letterio Runza; Alessandro de Sire; Renzo Boldorini; Nicola Fusco
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

8.  Machine learning for detection of lymphedema among breast cancer survivors.

Authors:  Mei R Fu; Yao Wang; Chenge Li; Zeyuan Qiu; Deborah Axelrod; Amber A Guth; Joan Scagliola; Yvette Conley; Bradley E Aouizerat; Jeanna M Qiu; Gary Yu; Janet H Van Cleave; Judith Haber; Ying Kuen Cheung
Journal:  Mhealth       Date:  2018-05-29

9.  Limb Volume Changes and Activities of Daily Living: A Prospective Study.

Authors:  Jae Hyung Park; John Merriman; Abraham Brody; Jason Fletcher; Gary Yu; Eunjung Ko; Alejandra Yancey; Mei R Fu
Journal:  Lymphat Res Biol       Date:  2020-11-13       Impact factor: 2.349

10.  Model-Based Patterns of Lymphedema Symptomatology: Phenotypic and Biomarker Characterization.

Authors:  Mei R Fu; Bradley E Aouizerat; Gary Yu; Yvette Conley; Deborah Axelrod; Amber A Guth; Jean-Pierre Gagner; Jeanna M Qiu; David Zagzag
Journal:  Curr Breast Cancer Rep       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.